Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2021-2025
SKU ID :TNV-18336781 | Published Date: 23-Apr-2021 | No. of pages: 120Description
TOC
• Executive Summary
o Market overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 - 2025
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Type
o Market segments
o Comparison by Type
o Second-generation ALK inhibitors - Market size and forecast 2020-2025
o First-generation ALK inhibitors - Market size and forecast 2020-2025
o Third-generation ALK inhibitors - Market size and forecast 2020-2025
o Market opportunity by Type
• Customer Landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America - Market size and forecast 2020-2025
o Europe - Market size and forecast 2020-2025
o Asia - Market size and forecast 2020-2025
o ROW - Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Betta Pharmaceuticals Co. Ltd.
o Bio-Techne Corp.
o Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
o F. Hoffmann-La Roche Ltd.
o Helsinn Healthcare SA
o Merck KGaA
o Novartis AG
o Pfizer Inc.
o Takeda Pharmaceutical Co. Ltd.
o Turning Point Therapeutics Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibits
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global - Market size and forecast 2020 - 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 - 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition - Five forces 2020
• 21: Type - Market share 2020-2025 (%)
• 22: Comparison by Type
• 23: Second-generation ALK inhibitors - Market size and forecast 2020-2025 ($ million)
• 24: Second-generation ALK inhibitors - Year-over-year growth 2020-2025 (%)
• 25: First-generation ALK inhibitors - Market size and forecast 2020-2025 ($ million)
• 26: First-generation ALK inhibitors - Year-over-year growth 2020-2025 (%)
• 27: Third-generation ALK inhibitors - Market size and forecast 2020-2025 ($ million)
• 28: Third-generation ALK inhibitors - Year-over-year growth 2020-2025 (%)
• 29: Market opportunity by Type
• 30: Customer landscape
• 31: Market share by geography 2020-2025 (%)
• 32: Geographic comparison
• 33: North America - Market size and forecast 2020-2025 ($ million)
• 34: North America - Year-over-year growth 2020-2025 (%)
• 35: Europe - Market size and forecast 2020-2025 ($ million)
• 36: Europe - Year-over-year growth 2020-2025 (%)
• 37: Asia - Market size and forecast 2020-2025 ($ million)
• 38: Asia - Year-over-year growth 2020-2025 (%)
• 39: ROW - Market size and forecast 2020-2025 ($ million)
• 40: ROW - Year-over-year growth 2020-2025 (%)
• 41: Key leading countries
• 42: Market opportunity by geography ($ million)
• 43: Impact of drivers and challenges
• 44: Vendor landscape
• 45: Landscape disruption
• 46: Industry risks
• 47: Vendors covered
• 48: Market positioning of vendors
• 49: Betta Pharmaceuticals Co. Ltd. - Overview
• 50: Betta Pharmaceuticals Co. Ltd. - Product and service
• 51: Betta Pharmaceuticals Co. Ltd. - Key offerings
• 52: Betta Pharmaceuticals Co. Ltd. - Key customers
• 53: Betta Pharmaceuticals Co. Ltd. - Segment focus
• 54: Bio-Techne Corp. - Overview
• 55: Bio-Techne Corp. - Business segments
• 56: Bio-Techne Corp. - Key offerings
• 57: Bio-Techne Corp. - Key customers
• 58: Bio-Techne Corp. - Segment focus
• 59: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Overview
• 60: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Product and service
• 61: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Key offerings
• 62: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Key customers
• 63: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Segment focus
• 64: F. Hoffmann-La Roche Ltd. - Overview
• 65: F. Hoffmann-La Roche Ltd. - Business segments
• 66: F. Hoffmann-La Roche Ltd. - Key offerings
• 67: F. Hoffmann-La Roche Ltd. - Key customers
• 68: F. Hoffmann-La Roche Ltd. - Segment focus
• 69: Helsinn Healthcare SA - Overview
• 70: Helsinn Healthcare SA - Product and service
• 71: Helsinn Healthcare SA - Key offerings
• 72: Helsinn Healthcare SA - Key customers
• 73: Helsinn Healthcare SA - Segment focus
• 74: Merck KGaA - Overview
• 75: Merck KGaA - Business segments
• 76: Merck KGaA - Key offerings
• 77: Merck KGaA - Key customers
• 78: Merck KGaA - Segment focus
• 79: Novartis AG - Overview
• 80: Novartis AG - Business segments
• 81: Novartis AG - Key offerings
• 82: Novartis AG - Key customers
• 83: Novartis AG - Segment focus
• 84: Pfizer Inc. - Overview
• 85: Pfizer Inc. - Business segments
• 86: Pfizer Inc. - Key offerings
• 87: Pfizer Inc. - Key customers
• 88: Pfizer Inc. - Segment focus
• 89: Takeda Pharmaceutical Co. Ltd. - Overview
• 90: Takeda Pharmaceutical Co. Ltd. - Product and service
• 91: Takeda Pharmaceutical Co. Ltd. - Key offerings
• 92: Takeda Pharmaceutical Co. Ltd. - Key customers
• 93: Takeda Pharmaceutical Co. Ltd. - Segment focus
• 94: Turning Point Therapeutics Inc. - Overview
• 95: Turning Point Therapeutics Inc. - Product and service
• 96: Turning Point Therapeutics Inc. - Key offerings
• 97: Turning Point Therapeutics Inc. - Key customers
• 98: Turning Point Therapeutics Inc. - Segment focus
• 99: Currency conversion rates for US$
• 100: Research Methodology
• 101: Validation techniques employed for market sizing
• 102: Information sources
• 103: List of abbreviations
Tables & Figures
Companies
Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., F. Hoffmann-La Roche Ltd., Helsinn Healthcare SA, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Turning Point Therapeutics Inc.
- PRICE
-
$2500$5000Buy Now